Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.78 Billion INR | 1.82% |
| 2022 | 1.74 Billion INR | -7.81% |
| 2021 | 1.89 Billion INR | 19.21% |
| 2020 | 1.59 Billion INR | 19.0% |
| 2019 | 1.33 Billion INR | -6.02% |
| 2018 | 1.42 Billion INR | 13.1% |
| 2017 | 1.25 Billion INR | 3.11% |
| 2016 | 1.22 Billion INR | 4.86% |
| 2015 | 1.16 Billion INR | -2.58% |
| 2014 | 1.19 Billion INR | 0.0% |
| 2011 | 1.48 Billion INR | -5.25% |
| 2010 | 1.56 Billion INR | -2.26% |
| 2009 | 1.6 Billion INR | -34.33% |
| 2008 | 2.44 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 1.78 Billion INR | 1.82% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.78 Billion INR | 0.0% |
| 2023 Q2 | 1.78 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.74 Billion INR | -7.81% |
| 2022 Q2 | 1.82 Billion INR | 0.0% |
| 2022 Q4 | 1.74 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1.73 Billion INR | 0.0% |
| 2021 Q4 | 1.89 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 1.89 Billion INR | 19.21% |
| 2020 FY | 1.59 Billion INR | 19.0% |
| 2020 Q4 | 1.59 Billion INR | 0.0% |
| 2020 Q2 | 1.5 Billion INR | 0.0% |
| 2019 Q4 | 1.33 Billion INR | 0.0% |
| 2019 Q2 | 1.3 Billion INR | 0.0% |
| 2019 FY | 1.33 Billion INR | -6.02% |
| 2018 Q4 | 1.42 Billion INR | 0.0% |
| 2018 Q2 | 1.23 Billion INR | 0.0% |
| 2018 FY | 1.42 Billion INR | 13.1% |
| 2017 Q4 | 1.25 Billion INR | 0.0% |
| 2017 Q2 | 1.23 Billion INR | 0.0% |
| 2017 FY | 1.25 Billion INR | 3.11% |
| 2016 FY | 1.22 Billion INR | 4.86% |
| 2016 Q2 | 1.18 Billion INR | 0.0% |
| 2016 Q4 | 1.22 Billion INR | 0.0% |
| 2015 FY | 1.16 Billion INR | -2.58% |
| 2015 Q4 | 1.16 Billion INR | 0.0% |
| 2015 Q2 | 1.07 Billion INR | 0.0% |
| 2014 FY | 1.19 Billion INR | 0.0% |
| 2013 Q3 | 1.37 Billion INR | 0.0% |
| 2012 Q2 | 1.42 Billion INR | 0.0% |
| 2011 FY | 1.48 Billion INR | -5.25% |
| 2011 Q4 | 1.48 Billion INR | 0.0% |
| 2010 FY | 1.56 Billion INR | -2.26% |
| 2009 FY | 1.6 Billion INR | -34.33% |
| 2008 FY | 2.44 Billion INR | 0.0% |
| 2008 Q4 | 2.44 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 97.236% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.605% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 93.749% |
| Granules India Limited | 55.2 Billion INR | 96.773% |
| Indoco Remedies Limited | 21.44 Billion INR | 91.692% |
| Achyut Healthcare Limited | 309.52 Million INR | -475.645% |
| Ajanta Pharma Limited | 46.38 Billion INR | 96.159% |
| Alkem Laboratories Limited | 155.74 Billion INR | 98.856% |
| Alpa Laboratories Limited | 1.82 Billion INR | 2.435% |
| Brooks Laboratories Limited | 904.45 Million INR | -96.997% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 83.472% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 76.713% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 85.322% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.54% |
| Eris Lifesciences Limited | 70.48 Billion INR | 97.472% |
| FDC Limited | 24.68 Billion INR | 92.781% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 98.759% |
| Gufic Biosciences Limited | 10.92 Billion INR | 83.692% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 84.707% |
| Ipca Laboratories Limited | 111.01 Billion INR | 98.395% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | 17.921% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -18.099% |
| Laurus Labs Limited | 83.87 Billion INR | 97.876% |
| Lupin Limited | 239.97 Billion INR | 99.258% |
| Mankind Pharma Limited | 119.63 Billion INR | 98.511% |
| Medicamen Biotech Limited | 2.94 Billion INR | 39.504% |
| Medico Remedies Limited | 961.95 Million INR | -85.222% |
| Megasoft Limited | 3.65 Billion INR | 51.305% |
| NATCO Pharma Limited | 69.06 Billion INR | 97.42% |
| Piramal Pharma Limited | 153.11 Billion INR | 98.836% |
| RPG Life Sciences Limited | 5.12 Billion INR | 65.259% |
| Sigachi Industries Limited | 6.94 Billion INR | 74.332% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.792% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 92.095% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 55.97% |
| Unichem Laboratories Limited | 31.69 Billion INR | 94.378% |
| Wanbury Limited | 3.43 Billion INR | 48.129% |
| Windlas Biotech Limited | 6.26 Billion INR | 71.547% |
| ZIM Laboratories Limited | 4.46 Billion INR | 60.124% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 99.391% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 65.406% |
| Divi's Laboratories Limited | 154.7 Billion INR | 98.848% |
| Hester Biosciences Limited | 6.62 Billion INR | 73.099% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 77.57% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 51.434% |
| Bal Pharma Limited | 3.2 Billion INR | 44.388% |
| Strides Pharma Science Limited | 58.39 Billion INR | 96.949% |
| Venus Remedies Limited | 6.26 Billion INR | 71.575% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 93.1% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 91.868% |
| Shilpa Medicare Limited | 30.93 Billion INR | 94.24% |
| Aarti Drugs Limited | 24.32 Billion INR | 92.675% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 92.061% |
| Suven Life Sciences Limited | 2.84 Billion INR | 37.461% |
| Ind-Swift Limited | 6.54 Billion INR | 72.776% |
| Valiant Laboratories Limited | 3.42 Billion INR | 48.007% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 95.539% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 92.421% |
| Themis Medicare Limited | 5.66 Billion INR | 68.544% |
| Hikal Limited | 24.87 Billion INR | 92.836% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 98.817% |
| Sequent Scientific Limited | 15.4 Billion INR | 88.433% |
| Novartis India Limited | 9.24 Billion INR | 80.736% |
| Wockhardt Limited | 76.49 Billion INR | 97.671% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 98.457% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -278.429% |
| Neuland Laboratories Limited | 18.32 Billion INR | 90.277% |
| Morepen Laboratories Limited | 12.93 Billion INR | 86.222% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | 25.78% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | 46.562% |